BUPIVACAINE HYDROCHLORIDE IN DEXTROSE INJECTION USP 7.5 MG
BUPIVACAINE HYDROCHLORIDE : 7.5 MG · DIN 02536714 · FORMATIVE PHARMA INC.
Health Canada status: MARKETED
What is BUPIVACAINE HYDROCHLORIDE IN DEXTROSE INJECTION USP?
BUPIVACAINE HYDROCHLORIDE IN DEXTROSE INJECTION USP 7.5 MG contains BUPIVACAINE HYDROCHLORIDE : 7.5 MG. It is listed in the Health Canada Drug Product Database under DIN 02536714, held by FORMATIVE PHARMA INC., supplied as SOLUTION for INTRASPINAL administration. Health Canada currently lists it as marketed, status dated 19-Mar-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is BUPIVACAINE HYDROCHLORIDE IN DEXTROSE INJECTION USP used for?
Production of local or regional anaesthesia and analgesia for subarachnoid (spinal) blocks in adults.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02536714 |
|---|---|
| Brand name | BUPIVACAINE HYDROCHLORIDE IN DEXTROSE INJECTION USP |
| Generic / active ingredient | BUPIVACAINE HYDROCHLORIDE : 7.5 MG |
| Manufacturer | FORMATIVE PHARMA INC. |
| Strength | 7.5 MG |
| Dosage form | SOLUTION |
| Route of administration | INTRASPINAL |
| Schedule | Ethical |
| ATC code | N01BB01 BUPIVACAINE |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 19-Mar-2024 |
How is it administered?
For subarachnoid (spinal) block. Dosage depends on area, vascularity, and patient status. Use lowest effective dose. Adults: 0.75% hyperbaric solution. Injections should be made slowly.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (Table of Contents lists section 10, but text ends at section 8).
How is it supplied?
Not explicitly detailed in provided text (mentions ampoules in general precautions).
Contraindications
Hypersensitivity to amide-type anesthetics; severe shock; heart block; inflammation/sepsis at injection site. Spinal specific: CNS diseases (meningitis, tumors), spinal hemorrhage, septicemia.
Warnings and precautions
Risk of dose-related toxicity, cardiac arrest, and death. Must have resuscitative equipment available. Spinal blocks may cause hypotension and bradycardia. Not for IV injection.
Is BUPIVACAINE in shortage in Canada?
A Canadian shortage report is on file for this molecule: Active — reported by OMEGA LABORATORIES LIMITED, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
Check availability for BUPIVACAINE HYDROCHLORIDE IN DEXTROSE INJECTION USP
What can be used instead?
Other Canadian products sharing ATC code N01BB01 BUPIVACAINE. 10 of 42 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| BUPIVACAINE HYDROCHLORIDE IN DEXTROSE INJECTION USP | 7.5 MG | SOLUTION | OMEGA LABORATORIES LIMITED | MARKETED | DIN 02512424 |
| BUPIVACAINE HYDROCHLORIDE IN DEXTROSE INJECTION USP | 7.5 MG | SOLUTION | STERIMAX INC | MARKETED | DIN 02460645 |
| BUPIVACAINE HYDROCHLORIDE INJECTION, USP | 7.5 MG | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02488930 |
| BUPIVACAINE INJECTION BP | 2.5 MG | SOLUTION | STERIMAX INC | MARKETED | DIN 02443686 |
| BUPIVACAINE INJECTION BP | 5 MG | SOLUTION | STERIMAX INC | MARKETED | DIN 02443694 |
| MARCAINE | 150 MG / 20 ML | SOLUTION | PFIZER CANADA ULC | MARKETED | DIN 02241917 |
| MARCAINE | 250 MG / 50 ML | SOLUTION | PFIZER CANADA ULC | MARKETED | DIN 02305909 |
| SENSORCAINE | 2.5 MG | SOLUTION | ASPEN PHARMACARE CANADA INC. | MARKETED | DIN 01976141 |
| SENSORCAINE | 5 MG | SOLUTION | ASPEN PHARMACARE CANADA INC. | MARKETED | DIN 01976168 |
| BUPIVACAINE HEAVY INJECTION BP | 15 MG / 2 ML | SOLUTION | AURO PHARMA INC | APPROVED | DIN 02470616 |
Who else supplies BUPIVACAINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. BUPIVACAINE appears in 19 registered pack listings across 5 markets, published on 5 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Request a quote for BUPIVACAINE HYDROCHLORIDE IN DEXTROSE INJECTION USP
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.